(EXEL) Exelixis - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30161Q1040

Stock:

Total Rating 47

Risk 90

Buy Signal -0.34

Biotechnology +3.6
Biotechnology +1.9

Market Cap: 11,813m
Avg Trading Vol: 121M USD

ATR: 3.81%
Peers RS (IBD): 17.50

Risk 5d forecast
Volatility	40.1%
Relative Tail Risk	-25.7%

Reward TTM
Sharpe Ratio	0.25
Alpha	-9.64

Character TTM
Beta	0.923
Beta Downside	0.661

Drawdowns 3y
Max DD	25.34%
CAGR/Max DD	1.40

EPS (Earnings per Share)

EPS CAGR: 50.39%
EPS Trend: 83.9%

Last SUE: 1.06
Qual. Beats: 1

Revenue

Rev. CAGR: 14.87%
Rev. Trend: 89.5%

Last SUE: -0.01
Qual. Beats: 0

Description: EXEL Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income: 782.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.30 > 0.02 and ΔFCF/TA 8.70 > 1.0
NWC/Revenue: 44.72% < 20% (prev 49.05%; Δ -4.33% < -1%)
CFO/TA 0.31 > 3% & CFO 884.3m > Net Income 782.6m
Net Debt (-309.4m) to EBITDA (934.7m): -0.33 < 3
Current Ratio: 3.56 > 1.5 & < 3
Outstanding Shares: last quarter (281.9m) vs 12m ago 0.05% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 80.11% > 50% (prev 73.57%; Δ 6.54% > 0%)
Interest Coverage Ratio: -25.43 > 6 (EBITDA TTM 934.7m / Interest Expense TTM -35.6m)

Altman Z'' 4.29

A: 0.36 (Total Current Assets 1.44b - Total Current Liabilities 405.6m) / Total Assets 2.84b
B: -0.03 (Retained Earnings -76.8m / Total Assets 2.84b)
C: 0.31 (EBIT TTM 905.6m / Avg Total Assets 2.90b)
D: -0.11 (Book Value of Equity -73.1m / Total Liabilities 683.1m)
Altman-Z'' Score: 4.29 = AA

Beneish M -2.97

DSRI: 1.01 (Receivables 286.9m/265.4m, Revenue 2.32b/2.17b)
GMI: 1.00 (GM 96.39% / 96.49%)
AQI: 1.06 (AQ_t 0.40 / AQ_t-1 0.38)
SGI: 1.07 (Revenue 2.32b / 2.17b)
TATA: -0.04 (NI 782.6m - CFO 884.3m) / TA 2.84b)
Beneish M-Score: -2.97 (Cap -4..+1) = A

What is the price of EXEL shares?

As of March 04, 2026, the stock is trading at USD 40.74 with a total of 3,447,359 shares traded.
Over the past week, the price has changed by -9.75%, over one month by -4.34%, over three months by -7.43% and over the past year by +5.68%.

Is EXEL a buy, sell or hold?

Exelixis has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy EXEL.

StrongBuy: 7
Buy: 4
Hold: 9
Sell: 0
StrongSell: 0

What are the forecasts/targets for the EXEL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	47.2	15.8%
Analysts Target Price	47.2	15.8%

EXEL Fundamental Data Overview March 01, 2026

P/E Trailing = 15.8489
P/E Forward = 14.2248
P/S = 5.0915
P/B = 5.319
P/EG = 2.2685
Revenue TTM = 2.32b USD
EBIT TTM = 905.6m USD
EBITDA TTM = 934.7m USD
Long Term Debt = 173.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 173.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -309.4m USD (from netDebt column, last quarter)
Enterprise Value = 10.93b USD (11.81b + Debt 173.0m - CCE 1.06b)
Interest Coverage Ratio = -25.43 (Ebit TTM 905.6m / Interest Expense TTM -35.6m)
EV/FCF = 12.72x (Enterprise Value 10.93b / FCF TTM 859.2m)
FCF Yield = 7.86% (FCF TTM 859.2m / Enterprise Value 10.93b)
FCF Margin = 37.03% (FCF TTM 859.2m / Revenue TTM 2.32b)
Net Margin = 33.73% (Net Income TTM 782.6m / Revenue TTM 2.32b)
Gross Margin = unknown ((Revenue TTM 2.32b - Cost of Revenue TTM 83.7m) / Revenue TTM)
Tobins Q-Ratio = 3.84 (Enterprise Value 10.93b / Total Assets 2.84b)
Interest Expense / Debt = 15.20% (Interest Expense 26.3m / Debt 173.0m)
Taxrate = 3.23% (8.16m / 252.7m)
NOPAT = 876.4m (EBIT 905.6m * (1 - 3.23%))
Current Ratio = 3.56 (Total Current Assets 1.44b / Total Current Liabilities 405.6m)
Debt / Equity = 0.08 (Debt 173.0m / totalStockholderEquity, last quarter 2.16b)
Debt / EBITDA = -0.33 (Net Debt -309.4m / EBITDA 934.7m)
Debt / FCF = -0.36 (Net Debt -309.4m / FCF TTM 859.2m)
Total Stockholder Equity = 2.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 27.02% (Net Income 782.6m / Total Assets 2.84b)
RoE = 36.89% (Net Income TTM 782.6m / Total Stockholder Equity 2.12b)
RoCE = 39.47% (EBIT 905.6m / Capital Employed (Equity 2.12b + L.T.Debt 173.0m))
RoIC = 41.31% (NOPAT 876.4m / Invested Capital 2.12b)
WACC = 9.39% (E(11.81b)/V(11.99b) * Re(9.31%) + D(173.0m)/V(11.99b) * Rd(15.20%) * (1-Tc(0.03)))
Discount Rate = 9.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -5.11%
[DCF] Terminal Value 76.89% ; FCFF base≈769.0m ; Y1≈948.6m ; Y5≈1.62b
[DCF] Fair Price = 83.12 (EV 21.28b - Net Debt -309.4m = Equity 21.59b / Shares 259.7m; r=9.39% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 83.87 | EPS CAGR: 50.39% | SUE: 1.06 | # QB: 1
Revenue Correlation: 89.48 | Revenue CAGR: 14.87% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.81 | Chg7d=+0.000 | Chg30d=+0.026 | Revisions Net=+1 | Analysts=11
EPS current Year (2026-12-31): EPS=3.39 | Chg7d=+0.000 | Chg30d=+0.010 | Revisions Net=+2 | Growth EPS=+10.2% | Growth Revenue=+11.4%
EPS next Year (2027-12-31): EPS=4.00 | Chg7d=+0.000 | Chg30d=-0.101 | Revisions Net=+2 | Growth EPS=+17.8% | Growth Revenue=+14.3%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.0% (Discount Rate 9.3% - Earnings Yield 6.3%)
[Growth] Growth Spread = +8.0% (Analyst 11.0% - Implied 3.0%)

Additional Sources for EXEL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle